Sanofi integrating, learning from Genzyme

01/12/2012 | Boston Globe (tiered subscription model), The

Sanofi is streamlining its operations after its purchase of Genzyme, CEO Christopher Viehbacher said at the annual JPMorgan Chase Healthcare Conference. Genzyme's labs will be maintained and a Sanofi research facility in New Jersey will be closed. "Genzyme's having a big impact on the Sanofi culture," Viehbacher said. Genzyme is good at testing targets early to ensure success, he said, and "that's a skill the industry is going to need to have."

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief: